CNTG | Centogene N.V. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.3250 - 0.4290
52 Week Range	0.2510 - 1.5300
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	7,229,138
Average Volume	265,720
Shares Outstanding	29,000,100
Market Cap	9,425,033
Sector	Healthcare
Industry	Medical - Diagnostics & Research
IPO Date	2019-11-07

Valuation
Profitability
Growth
Health
P/E Ratio	-0.23
Forward P/E Ratio	-0.51
EPS	-1.39
1YR Price Target	6.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	384
Country	Germany
Website	CNTG

Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.

CNTG's peers: GTH, FONR, XGN, SERA, SHC, OLK, MDXH, NOTV, STRRP, LMDX, STRR, MYNZ, BDSX, ACRS, CSTL, PRE

*Chart delayed

Analyzing fundamentals for CNTG we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CNTG Fundamentals page.

Watching at CNTG technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CNTG Technicals page.